Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
anabolic steroid androgen |
| gptkbp:CASNumber |
434-22-0
|
| gptkbp:foundIn |
human body (trace amounts)
urine after administration |
| gptkbp:hasMolecularFormula |
C18H26O2
|
| gptkbp:hasSMILES |
CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
|
| https://www.w3.org/2000/01/rdf-schema#label |
(17β)-19-nortestosterone
|
| gptkbp:is_banned_by |
gptkb:World_Anti-Doping_Agency
|
| gptkbp:is_derivative_of |
testosterone
|
| gptkbp:IUPACName |
estr-4-en-17β-ol-3-one
|
| gptkbp:meltingPoint |
122–124 °C
|
| gptkbp:metabolism |
gptkb:nandrolone_decanoate
gptkb:nandrolone_phenylpropionate |
| gptkbp:molecularWeight |
274.40 g/mol
|
| gptkbp:PubChem_CID |
9281
|
| gptkbp:routeOfAdministration |
oral
intramuscular injection |
| gptkbp:sideEffect |
liver toxicity
gynecomastia virilization |
| gptkbp:synonym |
gptkb:nandrolone
|
| gptkbp:usedFor |
performance-enhancing drug
treatment for anemia treatment for osteoporosis |
| gptkbp:bfsParent |
gptkb:nandrolone
|
| gptkbp:bfsLayer |
8
|